Hot Money Lover Rhine biological medium-term loss 9 million

Rhine Living Creature (002166, closing price 26.12 yuan) announcement of interim results today: The company lost or amounted to 9 million yuan in January-June this year.　　This or let everyone fall below the glasses. The company's first-quarter report in 2010 predicted net profits for the first half of the year that were attributable to owners of the parent company were less than 30% over a year earlier. After the correction, the company expects that the net profit attributable to the owner of the parent company in January-June this year will lose 700~900 million.　　The announcement showed that the net profit of the company belonging to the parent company in the same period last year was 5.2378 million yuan and the earnings per share was 0.08 yuan. According to previous reports, Rhine biological is the ability to produce the most complete varieties of plant extracts, one of the enterprises to master more than 200 kinds of plant extracts production technology, with a leading industry market adaptability.　　Company product structure Diversification, a single major species accounted for the proportion of company sales generally not more than 20%, can effectively disperse market risk. However, the company on the performance of the reasons for the difference, but it does not seem to reflect the company's market capacity and diversification of market risk capacity of the leading position. The announcement shows that the company's performance difference is due to the reporting period of the international market demand for plant extraction is small, the company's customers mainly distributed in North America and Europe, the demand for the region than last year's growth, and the company's product structure to make a large adjustment, all lead to reporting period company sales revenue significantly　　In addition, the company after the completion of the relocation of the company due to the cost of the same period year-on-year increase is also larger. In addition, Rhine biology is a A-share market is a well-deserved one, in the stock market, has been in the fall, in less than 1 months time, the share price has doubled, by the market known as "trading pioneer shares." At the same time, the Rhine biological is also known as the "popular lover" of the capital, in the stock price continues to soar behind the speculation that the shares of the floating capital across the country. I do not know now, Rhine Biology this mid-term deficit announcement, whether the hot money will still be on this "lover" still favor.